Abbott’s $21 Billion Bet on Cancer Tests After COVID Cash Dries Up
Abbott Laboratories is acquiring cancer test maker Exact Sciences for $21 billion. The deal comes as Abbott’s diagnostic division faces declining revenue from COVID tests that once generated over $8 billion annually.